

STP Northeast Regional Symposium

October 2, 2019

"Novel Preclinical models of acute and chronic graft-versus-host disease: How Predictive are they for a successful clinical translation?"

Regeneron Pharmaceuticals Inc.

(Building 3, 34-248/250)

777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

You are invited to join your colleagues for a day-long STP Regional Symposium entitled ""**Novel preclinical models of acute and chronic graft-versus-host disease: How predictive are they for a successful clinical translation?**"" to be held on October 2, 2019 at Regeneron Pharmaceuticals Inc., in Tarrytown, NY. There is no fee to attend, however, registration is required and we encourage you to register early as space is limited.

The presentation by Dr. Keith Mansfield will also be available as a webinar. See below for registration details. There is no deadline to register for the webinar.

Breakfast, snacks and lunch will be provided to attendees.

Thank you to Regeneron Pharmaceuticals Inc. for the generous contribution towards this event.

AGENDA

(Times are Eastern Daylight Time, EST)

8.00 AM-9.00 AM	Registration and Breakfast
9.00 AM-9.05 AM	Welcome Randy Soltys, PhD, DABT <i>Vice President, Drug Safety & Pharmacometrics, Regeneron Pharmaceuticals</i>
9.05 AM-9.15 AM	Introduction Prachi Sharma, BVSc, PhD, DACVP <i>Senior Staff Pathologist, Regeneron Pharmaceuticals Inc.</i>
9.15 AM-10.15 AM	Title: Modeling GVHD and organ transplant at Regeneron to support a therapeutic pipeline Keynote speaker: Dr. Matthew Sleeman, PhD Vice President Research, Immunology & Inflammation, Regeneron Pharmaceuticals
10.15 AM-10.45 AM	Title: GVHD: A Pathologist's Translational Perspective Speaker: Dan Weinstock, DVM, PhD, DACVP Scientific Director, Experimental and Molecular Pathology at Janssen R&D
10.45 AM-11.00 AM	Break
11.00 AM-Noon	Title: GvHD as a confounder in humanized mouse models of re-directed T cell therapies. Speaker: Keith Mansfield, DVM, DACVP Director, Discovery and Investigative Pathology at Novartis Institutes for BioMedical Research <i>(Also presented as a webinar. Registration for webinar is also required.)</i>
Noon-1.00 PM	Lunch
1.00 PM-1.30 PM	Title: GvHD Mouse Models for Preclinical Research: What's Broken and How Can We Fix it Speaker: Dinesh Bangari, BVSc, MVSc, PhD, DACVP <i>Associate Director, Global Discovery Pathology Translational In-vivo Models Global Research Platform, Sanofi Genzyme</i>

1.30 PM-2.00 PM	<p>Title: Pathology of Acute and Chronic GVHD in the Canine Model</p> <p>Speaker: Curtis Colleton, DVM, DACVP, PMP, CCA Fellow, Drug Safety & Pharmacometrics, Regeneron Pharmaceuticals</p>
2.00 PM-2.30 PM	<p>Title: Tissue-specific mechanisms of acute graft-versus-host disease: lessons from a pre-clinical non-human primate model.</p> <p>Speaker: Victor Tkachev, PhD Instructor in Pediatrics, Harvard Medical School</p>
2.30 PM-2.45 PM	Break
2.45 PM-3.15 PM	<p>Title: Cellular Engineering To Prevent Acute Graft vs Host Disease Following Human Allogeneic Stem Cell Transplantation.</p> <p>Speaker: Mitchell S. Cairo, M.D Chief, Pediatric Hematology, Oncology and Stem Cell Transplantation Professor of Pediatrics, Medicine, Pathology, Microbiology & Immunology and Cell Biology & Anatomy, New York Medical College</p>
3.15 PM-4.00 PM	<p>Panel discussion - All speakers</p> <p>Convener: Lekan Oyejide, DVM, PhD, DACVP <i>Senior Director, Pathology, Regeneron Pharmaceuticals</i></p>

Webinar Details:

Title: GvHD as a confounder in humanized mouse models of re-directed T cell therapies.

(Also presented as a webinar. Registration for webinar is also required)

Speaker: Keith Mansfield, DVM, DACVP

Description: Re-directed T cell therapies show promise as a highly effective approach to treat a variety of human hematologic and solid organ malignancies. Humanized mouse models are commonly used in early pharmacology studies to evaluate these therapies but are often confounded by the appearance of xenogenic Graft versus Host Disease (xGvHD) and must distinguished from off-tumor on/off-target toxicities. Manifestations of xGvHD can be influenced by a number of factors including host strain, preconditioning protocol, type of immune reconstitution and donor genetics.